Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-794858.06%
operating margin TTM
-618909.68%
revenue TTM
11.98 Thousand
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -1.59 |
| peg ratio | 0.03 |
| price to book ratio | 1.43 |
| price to sales ratio | 13,453.23 |
| enterprise value multiple | -2.58 |
| price fair value | 1.43 |
profitability ratios | |
|---|---|
| gross profit margin | -7422.58% |
| operating profit margin | -618909.68% |
| pretax profit margin | -794858.06% |
| net profit margin | -794858.06% |
| return on assets | -70.28% |
| return on equity | -85.71% |
| return on capital employed | -61.17% |
liquidity ratios | |
|---|---|
| current ratio | 7.23 |
| quick ratio | 7.23 |
| cash ratio | 2.46 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 855.84 |
| cash conversion cycle | -855.84 |
| receivables turnover | 0.00 |
| payables turnover | 0.43 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.11 |
| debt equity ratio | 0.14 |
| long term debt to capitalization | 0.13 |
| total debt to capitalization | 0.13 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -3.39 |
cash flow ratios | |
|---|---|
| free cash flow per share | -6.14 |
| cash per share | 11.61 |
| operating cash flow per share | -6.12 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -3.39 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -214.76 |
Frequently Asked Questions
When was the last time Lyell Immunopharma, Inc. (NASDAQ:LYEL) reported earnings?
Lyell Immunopharma, Inc. (LYEL) published its most recent earnings results on 06-05-2026.
What is Lyell Immunopharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Lyell Immunopharma, Inc. (NASDAQ:LYEL)'s trailing twelve months ROE is -85.71%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Lyell Immunopharma, Inc. (LYEL) currently has a ROA of -70.28%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did LYEL's net profit margin stand at?
LYEL reported a profit margin of -794858.06% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is LYEL's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.23 in the most recent quarter. The quick ratio stood at 7.23, with a Debt/Eq ratio of 0.14.